Inhibition of Glycogen Synthase Kinase and the Neuroprotective Function of Conjugated ZnO-Osthol Nanoparticles in Alzheimer's Disease.
Bioinorg Chem Appl
; 2022: 1401995, 2022.
Article
em En
| MEDLINE
| ID: mdl-39281976
ABSTRACT
A critical factor in the cause and progression of Alzheimer's disease (AD) is the growth of ß-amyloid peptide (Aß) in the brain. The mechanism of this effect is still unknown, although the effect of osthol on Aß-induced inflammation is neuroprotective in AD and supplementation with zinc might prevent or delay the onset of dementia. In the current study, by inducing APP vector in human BE (2)-M17 cells, we established a cellular model of AD and investigated the protective effect of osthol (7-methoxy-8-3-methyl-2-butenyl-2H-1-benzopyran-2-one)-zinc oxide nanoparticles. The osthol-conjugated zinc oxide nanoparticles could significantly increase cell viability by inhibiting cell apoptosis. Osthol treatment has also prevented synaptic proteins such as postsynaptic density-95 (PSD-95), synaptophysin (SYP), and synapsin-1 from decreasing in APP-induced BE (2)-M17 cells. In addition, the expression of miR-132 was significantly upregulated by osthol by triggering the Wnt/ß-catenin signaling pathway. We conclude from our observations that osthol is a potential drug for the treatment of a neurodegenerative disease, Alzheimer's. The key reason was that by upregulating miR-132, osthol could inhibit APP expression to prevent AD from occurring.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Revista:
Bioinorg Chem Appl
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Arábia Saudita